Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer

BMC Cancer

Miriam Lenhard¹  Sabine Heublein⁴  Christiane Kunert-Keil²  Thomas Vrekoussis⁴  Isabel Lomba⁴  Nina Ditsch¹  Doris Mayr³  Klaus Friese⁴  Udo Jeschke⁴ 

[1] Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Campus Grosshadern, Marchioninistr. 15, 81377 Munich, Germany

[2] Department of Orthodontics, Technische Universität Dresden, Fetscherstr. 74, 01309 Dresden, Germany

[3] Department of Pathology, Ludwig-Maximilians-University Munich, Thalkirchner Str. 36, 80337 Munich, Germany

[4] Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Campus Innenstadt, Maistr. 11, 80337 Munich, Germany

关键词: Prognosis;    In situ hybridization;    Immunohistochemistry;    Glycodelin A;    Glycodelin;    Endometrial cancer;   

Others  :  859176
DOI  :  10.1186/1471-2407-13-616

 received in 2013-07-22, accepted in 2013-12-18,  发布年份 2013

【 摘 要 】

Background

Knowledge on immunosuppressive factors in the pathogenesis of endometrial cancer is scarce. The aim of this study was to assess Glycodelin (Gd) and its immunosuppressive isoform Glycodelin A (GdA) in endometrial cancer tissue and to analyze its impact on clinical and pathological features and patient outcome.

Methods

292 patients diagnosed and treated for endometrial cancer were included. Patient characteristics, histology and follow-up data were available. Gd and GdA was determined by immunohistochemistry and in situ hybridization was performed for Gd mRNA.

Results

Endometrial cancer shows intermediate (52.2%) or high (20.6%) expression for Gd in 72.8%, and GdA in 71.6% (intermediate 62.6%, high 9.0%) of all cases. The glycosylation dependent staining of GdA is tumour specific and correlates with the peptide-specific Gd staining though neither of the two is associated with estrogen receptor, progesterone receptor or clinic-pathological features. Also Gd protein positively correlates with Gd mRNA as quantified by in situ hybridization. Gd positive cases have a favourable prognosis (p = 0.039), while GdA positive patients have a poor outcome (p = 0.003). Cox-regression analysis proofed GdA to be an independent prognostic marker for patient survival (p = 0.002), besides tumour stage, grade and the concomitant diagnosis of hypertension.

Conclusion

Gd and GdA are commonly expressed in endometrial cancer tissue and seem to be of relevance in tumourigenesis. They differ not only in glycosylation but also in their biological activity, since only GdA holds prognostic significance for a poor overall survival in endometrial cancer patients. This finding might be explained by GdAs immunosuppressive capacity.

【 授权许可】

   
2013 Lenhard et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V: Krebs in Deutschland 2005/2006. 7th edition. Berlin: Häufigkeiten und Trends; 2010.
• [2]Robert-Koch-Institut: Verbreitung von krebserkrankungen in Deutschland: Entwicklung der Prävalenz zwischen 1900 und 2010. Berlin; 2010.
• [3]Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591.
• [4]Wild S, Pierpoint T, Jacobs H, McKeigue P: Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000, 3(2):101-105.
• [5]Beral V, Bull D, Reeves G: Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 2005, 365(9470):1543-1551.
• [6]Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L, Hoover RN: Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case–control study. Am J Obstet Gynecol 1992, 167(5):1317-1325.
• [7]Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA: Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000, 11(2):185-192.
• [8]Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A, et al.: Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010, 127(2):442-451.
• [9]Mazurkiewicz JE, Bank JF, Joshi SG: Immunocytochemical localization of a progestagen-associated endometrial protein in the human decidua. J Clin Endocrinol Metab 1981, 52(5):1006-1008.
• [10]Joshi SG, Szarowski DH, Bank JF: Decidua-associated antigens in the baboon. Biol Reprod 1981, 25(3):591-598.
• [11]Morris HR, Dell A, Easton RL, Panico M, Koistinen H, Koistinen R, Oehninger S, Patankar MS, Seppala M, Clark GF: Gender-specific glycosylation of human glycodelin affects its contraceptive activity. J Biol Chem 1996, 271(50):32159-32167.
• [12]Julkunen M, Rutanen EM, Koskimies A, Ranta T, Bohn H, Seppala M: Distribution of placental protein 14 in tissues and body fluids during pregnancy. Br J Obstet Gynaecol 1985, 92(11):1145-1151.
• [13]Koistinen H, Easton RL, Chiu PC, Chalabi S, Halttunen M, Dell A, Morris HR, Yeung WS, Seppala M, Koistinen R: Differences in glycosylation and sperm-egg binding inhibition of pregnancy-related glycodelin. Biol Reprod 2003, 69(5):1545-1551.
• [14]Tse JY, Chiu PC, Lee KF, Seppala M, Koistinen H, Koistinen R, Yao YQ, Yeung WS: The synthesis and fate of glycodelin in human ovary during folliculogenesis. Mol Hum Reprod 2002, 8(2):142-148.
• [15]Chiu PC, Chung MK, Koistinen R, Koistinen H, Seppala M, Ho PC, Ng EH, Lee KF, Yeung WS: Cumulus oophorus-associated glycodelin-C displaces sperm-bound glycodelin-A and -F and stimulates spermatozoa-zona pellucida binding. J Biol Chem 2007, 282(8):5378-5388.
• [16]Yeung WS, Lee KF, Koistinen R, Koistinen H, Seppala M, Ho PC, Chiu PC: Roles of glycodelin in modulating sperm function. Mol Cell Endocrinol 2006, 250(1–2):149-156.
• [17]Seppala M, Koistinen H, Koistinen R, Chiu PC, Yeung WS: Glycosylation related actions of glycodelin: gamete, cumulus cell, immune cell and clinical associations. Hum Reprod Update 2007, 13(3):275-287.
• [18]Jeschke U, Toth B, Scholz C, Friese K, Makrigiannakis A: Glycoprotein and carbohydrate binding protein expression in the placenta in early pregnancy loss. J Reprod Immunol 2010, 85(1):99-105.
• [19]Rachmilewitz J, Riely GJ, Tykocinski ML: Placental protein 14 functions as a direct T-cell inhibitor. Cell Immunol 1999, 191(1):26-33.
• [20]Yaniv E, Borovsky Z, Mishan-Eisenberg G, Rachmilewitz J: Placental protein 14 regulates selective B cell responses. Cell Immunol 2003, 222(2):156-163.
• [21]Rachmilewitz J, Borovsky Z, Riely GJ, Miller R, Tykocinski ML: Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45. J Biol Chem 2003, 278(16):14059-14065.
• [22]Mukhopadhyay D, SundarRaj S, Alok A, Karande AA: Glycodelin A, not glycodelin S, is apoptotically active. Relevance of sialic acid modification. J Biol Chem 2004, 279(10):8577-8584.
• [23]Scholz C, Heublein S, Lenhard M, Friese K, Mayr D, Jeschke U: Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes 2012, 5(1):551. BioMed Central Full Text
• [24]Koistinen H, Seppala M, Nagy B, Tapper J, Knuutila S, Koistinen R: Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells. Am J Obstet Gynecol 2005, 193(6):1955-1960.
• [25]Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al.: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43(16):2434-2444.
• [26]Jeschke U, Kuhn C, Mylonas I, Schulze S, Friese K, Mayr D, Speer R, Briese V, Richter DU, Haase M, et al.: Development and characterization of monoclonal antibodies for the immunohistochemical detection of glycodelin A in decidual, endometrial and gynaecological tumour tissues. Histopathology 2006, 48(4):394-406.
• [27]Toth B, Roth K, Kunert-Keil C, Scholz C, Schulze S, Mylonas I, Friese K, Jeschke U: Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy. J Histochem Cytochem 2008, 56(5):477-485.
• [28]Mylonas I, Jeschke U, Kunert-Keil C, Shabani N, Dian D, Bauerfeind I, Kuhn C, Kupka MS, Friese K: Glycodelin A is expressed differentially in normal human endometrial tissue throughout the menstrual cycle as assessed by immunohistochemistry and in situ hybridization. Fertil Steril 2006, 86(5):1488-1497.
• [29]Bergemann C, Reimer T, Muller H, Hosel A, Briese V, Friese K, Jeschke U: Stimulation of hCG protein and mRNA levels in trophoblast tumour cells Jeg3 and BeWo by glycodelin A. Anticancer Res 2003, 23(2A):1107-1113.
• [30]Jeschke U, Wang X, Briese V, Friese K, Stahn R: Glycodelin and amniotic fluid transferrin as inhibitors of E-selectin-mediated cell adhesion. Histochem Cell Biol 2003, 119(5):345-354.
• [31]Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz C, Janni W, Kuhn C, Schroder E, Mayr D, Friese K: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem Cell Biol 2009, 131(2):283-295.
• [32]Jeschke U, Bischof A, Speer R, Briese V, Richter DU, Bergemann C, Mylonas I, Shabani N, Friese K, Karsten U: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors. Anticancer Res 2005, 25(3A):1581-1589.
• [33]Keil C, Husen B, Giebel J, Rune G, Walther R: Glycodelin mRNA is expressed in the genital tract of male and female rats (Rattus norvegicus). J Mol Endocrinol 1999, 23(1):57-66.
• [34]Kunert-Keil C, Jeschke U, Simms G, Kasper M: Increased expression of glycodelin mRNA and protein in rat lungs during ovalbumin-induced allergic airway inflammation. Histochem Cell Biol 2009, 131(3):383-390.
• [35]Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8(3):138-140.
• [36]Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15(1):10-17.
• [37]Deligdisch L, Holinka CF: Endometrial carcinoma: two diseases? Cancer Detect Prev 1987, 10(3–4):237-246.
• [38]Creasman WT: Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 1997, 24(1):S1-S140. S141-150
• [39]Kumar S, Shah JP, Bryant CS, Seward S, Ali-Fehmi R, Morris RT, Malone JM Jr: Radiation-associated endometrial cancer. Obstet Gynecol 2009, 113(2 Pt 1):319-325.
• [40]Denschlag D, Ulrich U, Emons G: The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int 2010, 108(34–35):571-577.
• [41]Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK: Impact of comorbid conditions on survival in endometrial cancer. Am J Clin Oncol 2012. [Epub ahead of print]
• [42]Julkunen M, Koistinen R, Sjoberg J, Rutanen EM, Wahlstrom T, Seppala M: Secretory endometrium synthesizes placental protein 14. Endocrinology 1986, 118(5):1782-1786.
• [43]Julkunen M, Koistinen R, Suikkari AM, Seppala M, Janne OA: Identification by hybridization histochemistry of human endometrial cells expressing mRNAs encoding a uterine beta-lactoglobulin homologue and insulin-like growth factor-binding protein-1. Mol Endocrinol 1990, 4(5):700-707.
• [44]Hautala LC, Koistinen R, Seppala M, Butzow R, Stenman UH, Laakkonen P, Koistinen H: Glycodelin reduces breast cancer xenograft growth in vivo. Int J Cancer 2008, 123(10):2279-2284.
• [45]Jeschke U, Mylonas I, Kunert-Keil C, Dazert E, Shabani N, Werling M, Kuhn C, Janni W, Gerber B, Friese K: Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence. Oncol Rep 2005, 13(3):413-419.
• [46]Mandelin E, Lassus H, Seppala M, Leminen A, Gustafsson JA, Cheng G, Butzow R, Koistinen R: Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res 2003, 63(19):6258-6264.
• [47]Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, et al.: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009, 27(12):2052-2058.
• [48]Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, et al.: Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 2009, 4(4):522-526.
• [49]Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, et al.: Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012, 30(18):2204-2210.
• [50]Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y: Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2005, 146(12):5365-5373.
• [51]Uchida H, Maruyama T, Ono M, Ohta K, Kajitani T, Masuda H, Nagashima T, Arase T, Asada H, Yoshimura Y: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2007, 148(2):896-902.
• [52]Uchida H, Maruyama T, Ohta K, Ono M, Arase T, Kagami M, Oda H, Kajitani T, Asada H, Yoshimura Y: Histone deacetylase inhibitor-induced glycodelin enhances the initial step of implantation. Hum Reprod 2007, 22(10):2615-2622.
• [53]Hautala LC, Greco D, Koistinen R, Heikkinen T, Heikkila P, Aittomaki K, Blomqvist C, Koistinen H, Nevanlinna H: Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients. Breast Cancer Res Treat 2011, 128(1):85-95.
• [54]Dell A, Morris HR, Easton RL, Panico M, Patankar M, Oehniger S, Koistinen R, Koistinen H, Seppala M, Clark GF: Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J Biol Chem 1995, 270(41):24116-24126.